RPSM
BHVN icon

Royalty Pharma Sub-Manager’s Biohaven BHVN Stock Holding History

Royalty Pharma Sub-Manager’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.7M Hold
2,936,507
– – 18.06% 4
2026
Q1 		$24.8M Hold
2,936,507
– – 14.38% 4
2025
Q4 		$33.2M Buy
+2,936,507
New +$36.4M 19.35% 3

Other funds holding BHVN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royalty Pharma Sub-Manager's BHVN Position: Q2 2026 in Review

Royalty Pharma Sub-Manager held its Biohaven (BHVN) position steady in Q2 2026 at 2,936,507 shares worth $43.7M. The position accounts for 18.06% of the portfolio, ranked #4.

Royalty Pharma Sub-Manager first reported a position in BHVN in Q4 2025 and has held it in 3 quarters since. 292 funds tracked by Wall St. Rank hold BHVN as of Q2 2026.

  • Royalty Pharma Sub-Manager held 2,936,507 shares of Biohaven worth $43.7M as of Q2 2026.
  • Royalty Pharma Sub-Manager left its Biohaven share count unchanged in Q2 2026.
  • Biohaven made up 18.06% of Royalty Pharma Sub-Manager's portfolio in Q2 2026, its #4 holding.
  • Royalty Pharma Sub-Manager first reported a position in Biohaven in Q4 2025 and has held it in 3 quarters since.
  • 292 funds tracked by Wall St. Rank held Biohaven as of Q2 2026.

Based on Royalty Pharma Sub-Manager's 13F filing for Q2 2026, filed 14 Aug 2026.